Matthew F. Brown - Concepedia

Author

Matthew F. Brown

Also Known As

Brown, Matthew F., M F Brown, M. Brown, M. F. BROWN, M.F. Brown, Matthew Brown, Matthew F Brown, Matthew F. Brown, Matthew Francis Brown, Michael F. Brown

127

Publications

5.1K

Citations

H-Index

113

Concepts

All Affiliations

Pfizer (United States)UPMC Hillman Cancer Center University of Pittsburgh University of California San Diego

About

Matthew F. Brown is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	3.1K
2	Natural Sciences	12	12	1.4K
3	Biochemistry	12	12	1.1K
4	Engineering	7	7	548
5	Health Sciences	3	3	173

Matthew F. Brown

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball, Science ImmunologyCell DeathImmunotherapyInflammationTranslational Medicine	2003	667
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson, European Journal of Cancer Surgical OncologyBone Sarcoma GroupGastrointestinal OncologyMedicinePathology	2004	442
Delineating the role of cooperativity in the design of potent PROTACs for BTK Adelajda Zorba, Chuong Nguyen, Yingrong Xu, Proceedings of the National Academy of Sciences EngineeringMolecular BiologyOrganic ChemistryChemistrySignaling Pathway	2018	409
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette, Journal of Medicinal Chemistry ImmunologyJanus Tyrosine KinasesImmunotherapyInflammatory ArthritisInflammation	2010	331
Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson, Journal of Medicinal Chemistry Combinatorial ChemistryDrug TargetThiol-reactive Covalent InhibitorsChemistryChemical Biology	2014	318
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition Jean‐Baptiste Telliez, Martin E. Dowty, Lu Wang, ACS Chemical Biology Jak1 InhibitionImmunologyImmune RegulationInnate ImmunityInflammatory Arthritis	2016	187
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( <i>S</i> )-2,2-Difluorocyclopropyl)((1 <i>R</i> ,5 <i>S</i> )-3-(2-((1-methyl-1 <i>H</i> -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) Andrew Fensome, Catherine M. Ambler, Eric P. Arnold, Journal of Medicinal Chemistry	2018	165
Lipid-protein interactions mediate the photochemical function of rhodopsin T. S. Wiedmann, Robert D. Pates, James M. Beach, Biochemistry Proteinlipid InteractionPhotoreceptor CellPhotochemistryBiochemistryNatural Sciences	1988	163
Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach, Journal of Medicinal Chemistry ImmunodeficienciesJanus KinasesImmunologyPharmacotherapyImmunotherapy	2018	160
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans Atli Thorarensen, Martin E. Dowty, Mary Ellen Banker, Journal of Medicinal Chemistry Specific InhibitorDrug TargetPharmacotherapyChemical BiologyPharmaceutical Chemistry	2017	158

Page 1